Pmv Pharmaceuticals, Inc. Financials
This page shows Pmv Pharmaceuticals, Inc. (PMVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
PMV’s cash reserve is being converted into research spending in an asset-light model with little balance-sheet leverage.
Cash slipped only modestly from the prior year, ending at$38.0M , but that stability is misleading because operating cash outflow widened to-$73.6M . The offset came from a positive investing inflow of$70.2M , so liquidity was supported by converting balance-sheet resources rather than by the business producing cash.
These are cash-real losses: net loss of
The company remains equity-financed, not debt-funded: total liabilities were only
Financial Health Signals
Pmv Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pmv Pharmaceuticals, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Pmv Pharmaceuticals, Inc. reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Pmv Pharmaceuticals, Inc. reported an operating loss of $86.2M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Pmv Pharmaceuticals, Inc.'s EBITDA was -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.1% from the prior year.
Pmv Pharmaceuticals, Inc. reported -$77.7M in net income in fiscal year 2025. This represents a decrease of 32.0% from the prior year.
Pmv Pharmaceuticals, Inc. earned -$1.48 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 29.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pmv Pharmaceuticals, Inc. recorded an outflow of $73.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 41.7% from the prior year.
Pmv Pharmaceuticals, Inc. held $38.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Pmv Pharmaceuticals, Inc.'s ROE was -74.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 40.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pmv Pharmaceuticals, Inc. invested $69.9M in research and development in fiscal year 2025. This represents an increase of 19.4% from the prior year.
Pmv Pharmaceuticals, Inc. invested $29K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.6% from the prior year.
Not reported for fiscal year 2025.
PMVP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $69.9M+19.4% | $58.5M+4.7% | $55.9M+7.5% | $52.0M+42.5% | $36.5M+52.5% | $23.9M+15.3% | $20.8M+49.9% | $13.9M |
| SG&A Expenses | N/A | $16.3M-39.3% | $26.9M+11.0% | $24.2M-3.2% | $25.1M+14.9% | $21.8M+98.0% | $11.0M+87.3% | $5.9M+16.7% | $5.0M |
| Operating Income | N/A | -$86.2M-0.9% | -$85.4M-6.6% | -$80.1M-4.0% | -$77.0M-32.2% | -$58.3M-66.8% | -$34.9M-31.2% | -$26.6M-41.0% | -$18.9M |
| Interest Expense | N/A | $6.3M-40.5% | $10.7M-4.6% | $11.2M+208.0% | $3.6M+707.8% | $449K-31.0% | $651K-50.0% | $1.3M-3.0% | $1.3M |
| Income Tax | N/A | -$2.2M+86.5% | -$16.1M-805100.0% | $2K+122.2% | -$9K-139.1% | $23K+283.3% | $6K-25.0% | $8K+166.7% | $3K |
| Net Income | N/A | -$77.7M-32.0% | -$58.9M+14.6% | -$69.0M+5.9% | -$73.3M-26.7% | -$57.8M-68.0% | -$34.4M-35.8% | -$25.4M-44.6% | -$17.5M |
| EPS (Diluted) | — | -$1.48-29.8% | -$1.14+20.8% | -$1.44+10.6% | -$1.61-25.8% | -$1.28 | -$2.40 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PMVP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $116.6M-39.1% | $191.3M-24.1% | $252.2M-6.7% | $270.3M-18.5% | $331.6M-9.3% | $365.5M+254.8% | $103.0M | N/A |
| Current Assets | $115.2M-34.4% | $175.7M-15.3% | $207.4M-16.0% | $247.0M-18.0% | $301.3M-17.4% | $364.8M+257.3% | $102.1M | N/A |
| Cash & Equivalents | $38.0M-7.1% | $40.9M+8.4% | $37.7M-65.2% | $108.3M-37.2% | $172.5M-52.3% | $361.4M+393.2% | $73.3M | N/A |
| Total Liabilities | $11.8M-22.1% | $15.2M-42.5% | $26.5M+9.0% | $24.3M+5.5% | $23.0M+259.0% | $6.4M-96.3% | $173.5M | N/A |
| Current Liabilities | $11.4M-20.6% | $14.4M+2.4% | $14.0M+29.5% | $10.8M-11.4% | $12.2M+90.6% | $6.4M+41.7% | $4.5M | N/A |
| Total Equity | $104.7M-40.5% | $176.1M-22.0% | $225.7M-8.3% | $246.0M-20.3% | $308.6M-14.1% | $359.1M+609.6% | -$70.5M-52.7% | -$46.1M |
| Retained Earnings | -$446.5M-21.1% | -$368.7M-18.9% | -$310.0M-28.6% | -$241.0M-43.7% | -$167.7M-52.6% | -$109.9M-45.7% | -$75.4M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PMVP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$71.3M | -$73.6M-43.5% | -$51.3M+7.9% | -$55.7M+12.7% | -$63.8M-36.9% | -$46.6M-42.2% | -$32.7M-48.4% | -$22.1M-45.4% | -$15.2M |
| Capital Expenditures | $14K | $29K-95.6% | $655K-31.9% | $962K-88.0% | $8.0M+491.8% | $1.3M+811.5% | $148K+35.8% | $109K-75.9% | $452K |
| Free Cash Flow | -$71.3M | -$73.6M-41.7% | -$51.9M+8.3% | -$56.6M+21.1% | -$71.7M-49.7% | -$47.9M-45.7% | -$32.9M-48.3% | -$22.2M-41.9% | -$15.6M |
| Investing Cash Flow | $39.1M | $70.2M+31.5% | $53.4M+205.6% | -$50.5M-3594.8% | -$1.4M+99.0% | -$143.6M-614.4% | $27.9M+763.9% | $3.2M-85.1% | $21.7M |
| Financing Cash Flow | $535K | $505K+61.3% | $313K-99.1% | $35.6M+3613.7% | $958K-52.6% | $2.0M-99.3% | $293.0M+374.0% | $61.8M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PMVP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -74.2%-40.8pp | -33.5%-2.9pp | -30.6%-0.8pp | -29.8%-11.0pp | -18.8%-9.2pp | -9.6% | N/A | N/A |
| Return on Assets | -66.7%-35.9pp | -30.8%-3.4pp | -27.4%-0.2pp | -27.1%-9.7pp | -17.4%-8.0pp | -9.4%+15.2pp | -24.6% | N/A |
| Current Ratio | 10.09-2.1x | 12.22-2.6x | 14.78-8.0x | 22.80-1.9x | 24.66-32.2x | 56.91+34.3x | 22.57 | N/A |
| Debt-to-Equity | 0.110.0x | 0.090.0x | 0.120.0x | 0.100.0x | 0.07+0.1x | 0.02 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Pmv Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is Pmv Pharmaceuticals, Inc. profitable?
No, Pmv Pharmaceuticals, Inc. (PMVP) reported a net income of -$77.7M in fiscal year 2025.
What is Pmv Pharmaceuticals, Inc.'s EBITDA?
Pmv Pharmaceuticals, Inc. (PMVP) had EBITDA of -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Pmv Pharmaceuticals, Inc.'s return on equity (ROE)?
Pmv Pharmaceuticals, Inc. (PMVP) has a return on equity of -74.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pmv Pharmaceuticals, Inc.'s free cash flow?
Pmv Pharmaceuticals, Inc. (PMVP) recorded an outflow of $73.6M in free cash flow during fiscal year 2025. This represents a -41.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pmv Pharmaceuticals, Inc.'s operating cash flow?
Pmv Pharmaceuticals, Inc. (PMVP) recorded an outflow of $73.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pmv Pharmaceuticals, Inc.'s total assets?
Pmv Pharmaceuticals, Inc. (PMVP) had $116.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pmv Pharmaceuticals, Inc.'s capital expenditures?
Pmv Pharmaceuticals, Inc. (PMVP) invested $29K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Pmv Pharmaceuticals, Inc. spend on research and development?
Pmv Pharmaceuticals, Inc. (PMVP) invested $69.9M in research and development during fiscal year 2025.
What is Pmv Pharmaceuticals, Inc.'s current ratio?
Pmv Pharmaceuticals, Inc. (PMVP) had a current ratio of 10.09 as of fiscal year 2025, which is generally considered healthy.
What is Pmv Pharmaceuticals, Inc.'s debt-to-equity ratio?
Pmv Pharmaceuticals, Inc. (PMVP) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pmv Pharmaceuticals, Inc.'s return on assets (ROA)?
Pmv Pharmaceuticals, Inc. (PMVP) had a return on assets of -66.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pmv Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Pmv Pharmaceuticals, Inc. (PMVP) had $38.0M in cash against an annual operating cash burn of $73.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Pmv Pharmaceuticals, Inc.'s Piotroski F-Score?
Pmv Pharmaceuticals, Inc. (PMVP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pmv Pharmaceuticals, Inc.'s earnings high quality?
Pmv Pharmaceuticals, Inc. (PMVP) reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pmv Pharmaceuticals, Inc. cover its interest payments?
Pmv Pharmaceuticals, Inc. (PMVP) reported an operating loss of $86.2M against $6.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.